Text Size

Comparison of Self and Clinician Administered Rating Scales in Patients With ADHD

This study has been completed.
Sponsor:
Information provided by:
Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00711724
First received: July 3, 2008
Last updated: June 21, 2010
Last verified: June 2010
History of Changes
  Purpose

The primary objective is to establish the concurrent validity of the clinician administered Attention Deficit Hyperactivity Disorder-Rating Scale (ADHD-RS) and the patient administered Attention Deficit Hyperactivity Disorder Self Report Scale (ASRS) v1.1 Symptom Checklist.


Condition
Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Comparison of Self and Clinician Administered Rating Scales in Patients With Attention Deficit Hyperactivity Disorder (ADHD)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • The ADHD-RS and ASRS v1.1 Symptom Checklist scales [ Time Frame: Weeks 1, 2, 3, 4, 5, 6, 7, or 8 ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: July 2007
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
MGH 1
Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

  Eligibility

Ages Eligible for Study:   13 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who are enrolled in the study Protocol 2003-P-001313: "Prevention of Cigarette Smoking in ADHD Youth with CONCERTA."

Criteria

Inclusion Criteria:

  • Diagnosis of ADHD
  • Age 13-65* *Parental consent and patient's assent will be obtained for minors participating in this protocol (only adolescents aged 13-18 yrs old will be included in the MGH site)

Exclusion Criteria:

  • Inability to reliably report ADHD symptoms at the discretion of the investigator
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00711724

Locations
United States, Massachusetts
Massachusetts General Hospital
Cambridge, Massachusetts, United States, 02138
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: Paul Hammerness, MD Massachusetts General Hospital
  More Information

Additional Information:
Related Info  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Paul Hammerness, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00711724     History of Changes
Other Study ID Numbers: 2007-P-000911
Study First Received: July 3, 2008
Last Updated: June 21, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
Attention Deficit Hyperactivity Disorder (ADHD)
Adolescent

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Mental Disorders
 Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on June 17, 2013